中国临床药学杂志

目的 :探讨沙利度胺治疗多发性骨髓瘤 (MM)的临床有效性。方法 :初治、难治或复发MM患者 10例 ,沙利度胺起始剂量 5 0～ 2 0 0mg·d-1,每 2wk增加 5 0～ 2 0 0mg·d-1,直到患者能够耐受或有效 ;同时联合应用化疗。根据M蛋白评定疗效为完全缓解 (CR)、很好的部分缓解 (VGPR)、部分缓解 (PR)、微小反应 (MR)和无反应 (NR)。同时对贫血、骨髓浆细胞比例和其他如口腔溃疡等进行评价。结果 :CR 3例 ,VGPR 3例 ,PR 4例。平均随访时间 5 0 5wk ,总生存率 90 %,无病生存率 30 %。无不能耐受的不良反应。结论 :沙利度胺可作为初发或难治MM的治疗。

AIM: To investigate the efficacy of thalidomide in the treatment of patients with multiple myeloma (MM). METHODS: Ten patients with MM including newly diagnosed, refractory and relapse were received the treatment of thalidomide and chemotherapy. The initial dose of thalidomide was administered from 50 mg·d -1 to 200 mg·d -1, then increased from 50 mg·d -1 to 200 mg·d -1 every two weeks until the patients' maximal tolerance, chemotherapy was accompanied in some patients. The efficacy was divided as CR, VGPR, PR, MR and NR. Degree of anemia, percent of bone marrow plasma cells and other items such as oral ulcer were also observed. RESULTS: Three cases of patients obtained CR, 3 VGPR and 4 PR. The mean following duration was 50.5 wk, the overal survival rate was 90%, the disease-free survival rate was 30%. No un-tolerance adverse drug reaction was found. CONCLUSION: Thalidomide could been used as the first or salvage choice in the treatment of MM.